SMML #5 Focus on past and upcoming congresses and conferences

The goal of this newsletter is to give an overview of what is happening around multiple myeloma in terms of medical developments. This is achieved by monitoring news articles, PR releases and scientific reports on one hand. Conversations from HCPs, digital opinion leaders and other influencers attending congresses, offering their opinion on treatments and commenting on new developments on the other hand.

Objectives

Who will benefit from this newsletter? ​

Any professionals interested in keeping up with developments around multiple myeloma:

• Marketers
• Business Analysts
• But also HCPs who want to anticipate the future landscape of MM management

Scope

The scope of the analysis is focused on mentions coming worldwide.*​

There were a total of 19K mentions from patients recorded during the listening period from April 1st, 2023, to April 30th, 2023.

A majority of mentions came from News (48%), Twitter (40%), Instagram (5%), Forums (3%), Reddit (2%), Blogs (1%) and tumblr (1%).​

A total of 5K unique authors were identified.

*: Myeloma OR multiplemyeloma OR #Mmsm OR #Myeloma* OR #Curemyeloma* OR #Mmmrd OR #mmsm OR title: ("multiple myeloma" OR myeloma)

Methodology

Focus on meetings, congresses and conferences

This month, several meetings, congresses and conferences took place. While not specifically centered around multiple myeloma, several presentations during those events occurred, contributing to the volume seen in this category for MM. The most cited gatherings were the annual #EBMT23 meeting in Paris, France (European Society for Blood and Marrow Transplantation); the annual #AACR23 meeting in Florida, US (American Association for cancer research) and the #BSH2023 with their 63rd annual scientific meeting in Birmingham, UK (British Society for Haematology).

Share of voice: Topics of conversations

Share of voice: Molecules

Media (press release): volume and articles per peak

A

Oncolyze Announces FDA Orphan Drug Designation for OM-301 for the Treatment of Multiple Myeloma Link

Demonstration of Accurate Screening of Gene Dependency in Multiple Myeloma from Aitia’s Gemini Digital Twins to be Presented at 2023 AACR Annual Meeting Link

K36 Therapeutics announces dosing of first patient in KTX-1001 Phase 1 Clinical Trial for relapsed or refractory multiple myeloma and addition of Mr. Michael Heffernan as Independent Board Director Link

B

ALX Oncology Announces Clinical Trial Collaboration with Sanofi to Evaluate Evorpacept in Combination with SARCLISA (isatuximab-irfc) in Patients with Multiple Myeloma Link

Prognosis of Multiple Myeloma Has Improved Since 2000 Link

Multiple myeloma patients in Spain face regional disparities Link

C

Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple Myeloma Link

IU cancer center researcher leads first in-human multiple myeloma study with 90.5 percent response rate Link

BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating Motixafortide and G-CSF in Stem Cell Mobilization for Autologous Transplantation in Multiple Myeloma Link

Drug Market Watch

Fill this short form to discover the entire newsletter
and to receive next SMML newsletters directly in your mailbox!
👇 👇